Equity Overview
Price & Market Data
Price: $1.73
Daily Change: +$0.05 / 2.89%
Daily Range: $1.65 - $1.74
Market Cap: $144,787,888
Daily Volume: 1,517,392
Performance Metrics
1 Week: -1.16%
1 Month: -15.42%
3 Months: -29.46%
6 Months: 3.66%
1 Year: -17.48%
YTD: -15.84%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.